表位
抗原
主要组织相容性复合体
肽
CD8型
免疫系统
化学
T细胞
细胞毒性T细胞
抗原呈递
免疫疗法
抗原提呈细胞
肿瘤抗原
分子生物学
细胞生物学
生物
免疫学
生物化学
体外
作者
Shuting Bai,Hao Jiang,Yuanshuai Song,Yining Zhu,Ming Qin,Chun‐Ting He,Guangsheng Du,Xun Sun
标识
DOI:10.1016/j.jconrel.2022.02.027
摘要
Tumor peptide vaccines contain only key amino acid sequences of tumor neoantigens, and therefore can provide precise activation of immune responses. Recent research has found that short peptide vaccines restricted to MHC-I epitopes are insufficient to activate effective CD8+ T cell responses for tumor elimination, and assistance from CD4+ T cell immunity could significantly improve the therapeutic outcome. Herein, we proposed an innovative peptide vaccine strategy to simultaneously activate CD8+ and CD4+ T cell responses by combining MHC-I and MHC-II epitopes into one long peptide antigen. To further strengthen the anti-tumor immune response induced by this dual-epitope peptide, we engineered a PEG derivative (PpASE) stabilized aluminum nanoparticle for delivering the synthetic long peptides (ANLs). The synthesized nanovaccine with a diameter of ~100 nm showed good stability and enhanced antigen uptake by antigen-presenting cells (APCs). As a result, ANLs promoted the presentation of MHC-I epitope in APCs and induced stronger activation and proliferation of CD8+ T cells as compared to aluminum nanoparticle loaded with MHC-I epitope restricted peptides (ANSs). After subcutaneous vaccination, the developed nanovaccine significantly inhibited tumor growth and prolonged mouse survival in both B16-OVA and B16F10 tumor models. Finally, ANLs were also able to elevate the maturation level of human dendritic cells (DCs), showing a great possibility of clinical translation.
科研通智能强力驱动
Strongly Powered by AbleSci AI